Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases
Bayer HealthCare (Donation of moxifloxacin)
National Institutes of Health
Department for International Development
United States Agency for International Development
Department of Foreign Affairs and Trade, Australian Government
AIDS Clinical Trials Group
European and Developing Countries Clinical Trials Partnership (Grant IP.2007.32011.011)
Sanofi (Donation of rifampicin)
Bill and Melinda Gates Foundation (OPP1017459)
Directorate General for International Cooperation of the Netherlands
Received: 23 May 2017
Accepted: 25 September 2017
First Online: 27 October 2017
: MM – Clinician and Research Associate, University College London (UCL); PP – Medical Research Council (MRC) Senior Statistician; CM Senior VP Research and Development, TB Alliance; EB – Research Scientist, UCL/REMoxTB; AB – Post-doctoral Scientist, UCL; RH – Senior Research Associate, UCL; SM – Clinician and Research Associate, UCL; KPS – Clinician and Research Associate, UCL; MB – Associate Professor, London School of Hygiene and Tropical Medicine; AMC – MRC Senior Statistician; AJN – Senior scientist at MRC Clinical Trials Unit at UCL; SKM – Professor of Clinical Trials, MRC Clinical Trials Unit at UCL; ML – Reader, UCL Respiratory and Director UCL-TB Centre; TDM – Professor of Clinical Microbiology, UCL and Director, UCL Centre for Clinical Microbiology; SHG – Sir James Black Professor of Medicine, University of St Andrews.
: The UCL ethics committee and the ethics committees of all study sites and organisations approved the REMoxTB study; these are provided in Additional file InternalRef removed. Patients gave their informed consent for the REMoxTB study and for their specimens and data to be used for the purposes of this study [CitationRef removed].
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.